Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
INCB054329 is BET inhibitor, which inhibits cell proliferation (Proceedings of the 106th Annual Meeting of the AACR; 2015; Abstract nr 3525).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|INCB054329||INCB-054329||BET Inhibitor (Pan) 30||INCB054329 is BET inhibitor, which results in decreased expression of BET protein-regulated genes including MYC, potentially leading to decreased tumor cell proliferation (PMID: 30206163)|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||INCB054329||Preclinical - Cell line xenograft||Actionable||In a preclinical study, INCB054329 promoted apoptosis and decreased MYC expression in colorectal cancer cell lines in culture and demonstrated anti-tumor activity in colorectal cancer cell line xenograft models (AACR; 2015. Abstract nr 3525).||detail...|
|Unknown unknown||multiple myeloma||not applicable||INCB054329||Preclinical - Cell line xenograft||Actionable||In a preclinical study, INCB054329 treatment reduced MYC expression and proliferation of myeloma cell lines in culture, and inhibited tumor growth in myeloma cell line xenograft models (PMID: 30206163).||30206163|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02431260||Phase I||INCB054329||An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies||Terminated||USA||0|